Navigation Links
GeneTex Launches New Antibody Against Phosphorylated Histone H3 for Epigenetics Research
Date:12/10/2012

IRVINE, Calif., Dec. 10, 2012 /PRNewswire/ -- GeneTex, a leading manufacturer of antibodies and antibody-related reagents, is set to launch a new antibody against phosphorylated Histone H3. Histone proteins package and organize the DNA of eukaryotic cells into structural units referred to as nucleosomes, and the modification of histone tails plays a critical role in the modulation of gene transcription.

(Photo:  http://photos.prnewswire.com/prnh/20121210/LA26278)

(Logo:  http://photos.prnewswire.com/prnh/20111129/LA13485LOGO-b)

The phosphorylation of Histone H3 at serine residue 10 by Msk1 during interphase marks transcriptional activation. Aurora kinase B also phosphorylates Ser10, along with Ser28, at the onset of mitosis to initiate chromosome condensation. More recent evidence suggests that the phosphorylation of Histone H3 at Ser10 stimulates Lys14 acetylation and may also act as a "master switch" that prevents the abnormal phosphorylation of Histone H3 at other sites during mitosis.

GeneTex's new Histone H3 (phospho Ser10) antibody will allow researchers to further examine the role that histone phosphorylation plays in complex epigenetic processes. The antibody has been validated for western blotting in both human and mouse samples as well as for immunocytochemistry/immunofluorescence. For additional information on GeneTex, Inc. and its epigenetics antibodies, please call toll-free 877-GENETEX (436-3839) or visit www.genetex.com.

About GeneTex, Inc.

GeneTex, Inc. is an antibody company founded in 1997 by a group of internationally renowned scientists from academia. They strive to produce the highest quality antibodies and reagents. Their primary and secondary antibodies are created through a process involving extensive research, development and validation. GeneTex's catalog has grown to over 55,000 primary antibodies and all are backed by a 100% Satisfaction Guarantee. 

Corporate Mission

We strive to serve and accelerate life science research by creating essential life science tools where quality can be found in every vial.


'/>"/>
SOURCE GeneTex
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. GeneTex Antibody Company to Launch New Line of Primary Antibodies for the Study of Spindle Assembly
2. GeneTex, Inc. to Attend the 2012 Annual Meeting of the American Society for Cell Biology
3. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
4. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
5. BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
6. Ambry Genetics Launches Illumina MiSeq Next-Gen Sequencing Services
7. Neogen Launches Fully Quantitative Lateral Flow Test for DON
8. Exagen Diagnostics Launches Cutting-Edge Lupus Diagnostic
9. iHealth Lab Launches Personalized Web Portal to Store Your Vitals
10. Elsevier Launches Bilingual International Nursing Skill Training and Management Platform: NursingChina.com
11. Upsher-Smith Launches B-Nexa® Prescription Prenatal Vitamin With B Vitamins and Ginger for Nausea and Vomiting of Pregnancy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... The Fight Against Cancer Innovation Trust (FACIT) and the ... report that Fusion Pharmaceuticals Inc. (Fusion) has closed a ... – JJDC, Inc. (JJDC) as the lead investor. Additional, ... and Genesys Capital, as well as founding investor FACIT.  ... ...
(Date:2/23/2017)... , Feb. 23, 2017  In Atlanta, it seems ... fashion, and culture intertwine to create an expressive and dynamic ... reflect this energy and contribute to it. ... Hair Fairies seeks to carry on that tradition ... Atlanta salon is the newest of ...
(Date:2/23/2017)... , Feb. 23, 2017  Imanis Life ... product line of oncolytic vaccinia viruses for virotherapy ... as part of Genelux,s proprietary, vaccinia virus-based technology ... excited to enter into a partnership with Genelux ... oncolytic vaccinia viruses for use in research," said ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... that in a published evaluation of multiple immunoassay-based threat detection technologies by ... Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found to have ...
Breaking Biology Technology:
(Date:2/7/2017)... MINNETONKA, Minn. , Feb. 7, 2017   ... that supports the entire spectrum of clinical research, is ... iMedNet , its innovative, highly flexible and ... iMedNet customers. iMedNet is a ... only provides Electronic Data Capture (EDC), but also delivers ...
(Date:2/3/2017)... Feb. 3, 2017 A new independent identity ... Partners, LLP (IdSP) . Designed to fill a critical ... identity market, founding partners Mark Crego and ... years just in identity expertise that span federal governments, ... leadership. The Crego-Kephart combined expertise has a common theme ...
(Date:1/31/2017)... CAMBRIDGE, Mass. , Jan. 31, 2017 /PRNewswire-USNewswire/ ... develop novel therapies for the treatment of bacterial ... generation set of antibacterial candidates from Pro Bono ... the increased prevalence of multi-drug resistant forms of ... by Cantab Anti Infectives Ltd, a PBB group ...
Breaking Biology News(10 mins):